Daxotel 20 mg/vial (IV Infusion)

Title

• Daxotel

Categories

• Antineoplastic Agent
• Chemotherapy

Description

• Daxotel is a microtubule inhibitor indicated for treating various types of cancer including Breast Cancer, Non-small Cell Lung Cancer, Prostate Cancer, Gastric Adenocarcinoma, and Squamous Cell Carcinoma of the Head and Neck.

Color Options

• Clear

Functions

• Disrupts the microtubular network in cells important for vital mitotic and interphase cellular functions
• Promotes the assembly of tubulin into stable microtubules while inhibiting their disassembly

Materials

• Docetaxel

Technical Specifications

• Acts as a CYP3A4 substrate

Design Elements

• Promotes polymerization of microtubules leading to the production of microtubule bundles without normal function
• Stabilizes microtubules resulting in the inhibition of mitosis in cells

Usability Features

• Administered intravenously over 1 hr every 3 weeks
• Premedication with oral corticosteroids is recommended
• Store between 2°C and 25°C and protected from light

Dosage

• Dosage varies based on the type of cancer being treated, with different dosages for locally advanced or metastatic Breast Cancer, adjuvant Breast Cancer, non-small cell lung cancer, castration-resistant prostate cancer, gastric adenocarcinoma, and squamous cell carcinoma of the head and neck

Administration

• Administer in a facility equipped to manage possible complications such as anaphylaxis
• Use only a 21 gauge needle to withdraw docetaxel from the vial

Interaction

• Metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4

Contraindications

• Contraindicated in patients with neutrophil counts of less than 1500 cells/mm3
• History of severe hypersensitivity reactions to docetaxel or to other drugs formulated with polysorbate 80

Side Effects

• Common adverse reactions include infections, neutropenia, febrile neutropenia, hypersensitivity, thrombocytopenia, neuropathy, dysgeusia, dyspnea, constipation, anorexia, nail disorders, fluid retention, asthenia, pain, nausea, diarrhea, vomiting, mucositis, alopecia, skin reactions, and myalgia

Pregnancy & Lactation

• Docetaxel can cause fetal harm when administered to a pregnant woman

Precautions & Warnings

• Should be administered under the supervision of a physician experienced in the use of antineoplastic agents
• Higher risk of severe adverse reactions in patients with hepatic impairment
• Should not be given to patients with neutrophil counts of less than 1500 cells/mm3
• Close monitoring for severe hypersensitivity reactions and treatment-related acute myeloid leukemia
• No studies conducted to assess the carcinogenic potential

Overdose Effects

• No known antidote for docetaxel overdose
• Complications may include bone marrow suppression, peripheral neurotoxicity, and mucositis
• Patients should receive therapeutic G-CSF as soon as possible after discovery of overdose

Therapeutic Class

• Cytotoxic Chemotherapy

Storage Conditions

• Store between 2°C and 25°C and protected from light
• Freezing does not adversely affect the product

Related Brands